Adalimumab is a promising therapy for children with Crohn's disease

Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

Steroids are commonly used in Crohn's disease, but can stunt growth and delay puberty. Incidence of this disease, which causes , is on the rise in children.

This study is the largest double-blind study of an anti-TNF agent in children with Crohn's disease. It found that more than 80 percent of children with moderate to severe Crohn's disease responded to within a month (response was defined as a decrease in Pediatric Crohn's Disease Activity Index ≥ 15 points from baseline). By six months, approximately 34 percent of patients were in clinical remission, and after a year, 28.4 percent were in remission.

The promising results of treatment with adalimumab are extremely encouraging, especially in this clinically challenging population resistant to conventional therapy. The goal of treatment is not only to induce and maintain clinical remission, but also to restore and preserve normal growth and pubertal development in these children.

Researchers studied 192 patients, ages 6 to 17 years, across 45 sites in Canada, Europe and the U.S. between April 2007 and May 2010. Depending on their body weight, patients were assigned to either a high-dose group, which received 40 mg of adalimumab every other week or 20 mg of adalimumab every other week. Patients assigned to a low-dose group either received 20 mg of adalimumab every other week or 10 mg of adalimumab every other week, again depending on their body weight. More children that received high than low dose were in at week 26, but the difference between dose groups was not statistically significant.

add to favorites email to friend print save as pdf

Related Stories

2-drug combo twice as effective for Crohn's disease remission

Apr 14, 2010

A study led by Mayo Clinic suggests remission from Crohn's disease may be more likely if patients get biologic therapy combined with immune-suppressing drugs first instead of immune-suppressing drugs alone. The study, published ...

Recommended for you

Senegal monitors contacts of 1st Ebola patient

11 hours ago

Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.

Cerebral palsy may be hereditary

16 hours ago

Cerebral palsy is a neurological developmental disorder which follows an injury to the immature brain before, during or after birth. The resulting condition affects the child's ability to move and in some ...

19 new dengue cases in Japan, linked to Tokyo park

22 hours ago

Japan is urging local authorities to be on the lookout for further outbreaks of dengue fever, after confirming another 19 cases that were contracted at a popular local park in downtown Tokyo.

User comments